Drug Profile
DAB389interleukin-6
Alternative Names: DAB389IL-6; interleukin-6 diphtheria toxin chimeric proteinLatest Information Update: 14 Feb 2001
Price :
$50
*
At a glance
- Originator Seragen
- Class Antineoplastics; Interleukins
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Feb 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 23 Nov 1998 New profile
- 23 Nov 1998 Preclinical development for Cancer in USA (Unknown route)